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Abstract
Background
This study aimed to describe patterns of long-term antithrombotic use in acute ischemic
stroke (AIS) patients with non-valvular atrial fibrillation (NVAF) in Korea and their impacts on
clinical events before introduction of non-vitamin K antagonist oral anticoagulants (NOAC)
into practice in 2015.
Methods
Patients with NVAF who were admitted due to the AIS and discharged no later than 2008
were enrolled retrospectively. Data were collected at 11 time points during the first 3 years
of follow-up. The primary outcome event was a composite of stroke recurrence, major bleed-
ing, and death. Vitamin K antagonist (VKA) users were categorized into a well-controlled
INR group and a poorly-controlled INR group (modified TTR�47.0% vs <47.0%).
Results
Of 1,350 patients enrolled in this study, 95% were on antithrombotic medications at dis-
charge. The rate of VKA usage decreased over time (77% and 40% at discharge and 3
years, respectively). The cumulative event rates of the primary outcome differed by treat-
ment patterns. Among the 10 most frequent treatment types, the highest outcome rate was
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observed in patients who started with VKA-only therapy but discontinued VKAs during fol-
low-up without restarting (70.2%); this was followed by those starting with antiplatelet-only
therapy and stopping it without restart (66.7%). Among VKA users, the 3-year cumulative
primary outcome rates were higher in the poorly-controlled INR group than the well-con-
trolled INR group (24.5% vs 15.7%; p = 0.015).
Conclusion
Our study revealed that, in pre-NOAC era, there was a wide spectrum of long-term antith-
rombotic use. The incidence of the composite outcome also varied by patterns of antithrom-
botic use.
Introduction
Atrial fibrillation (AF) confers a 5-fold increase in stroke risk and a 2-fold increase in mortal-
ity.[1] Recent studies have reported AF in 20–30% of incident ischemic stroke cases.[2–4]
Stroke with AF is more severe and associated with a more substantial societal burden than
stroke without AF.[5–8] In a population-based stroke registry study, the case-fatality in
patients with AF was shown to reach 50% at one-year after the index stroke.[6]
Current guidelines strongly recommend oral anticoagulant (OAC) therapy for the preven-
tion of recurrent stroke in patients with stroke and AF.[9, 10] Before non-vitamin K antagonist
oral anticoagulants (NOAC) were introduced and started to be reimbursed by the Korean gov-
ernment in mid-2015, standard OAC was vitamin K antagonist (VKA). Unpredictable and
variable metabolism due to genetic variations and food and drug interactions necessitate close
monitoring of the coagulation status of patients using VKA. This has led to the underuse of
VKA in practice. According to a recent study of the Registry of the Canadian Stroke Network,
one third of patients are not managed according to the recommendations (i.e., OAC alone),
although the use of VKA is associated with improved stroke outcomes, even in patients with
severe stroke.[11] A study by Riks-Stroke, the Swedish Stroke Register, showed that less than
half of ischemic stroke patients with AF maintained VKA treatments during the first 2 years
after discharge.[12] However, there has been no report on the long-term adherence to antith-
rombotic therapy in Korean stroke patients with AF.
The efficacy and safety of VKA are critically dependent on the percentage of the time when
International Normalized Ratio (INR) is maintained in time in therapeutic range (TTR).[13–
15] However, the TTR might be less than expected in Korean population,[16, 17] possibly due
to a high intake of vitamin K-rich foods and high frequency of genetic polymorphisms related
to unfavorable VKA metabolism.[18, 19]
This multicenter observational study aimed to describe the 3-year patterns of antithrombo-
tic use before the introduction of NOAC into practice in Korean non-valvular AF (NVAF)
patients who were hospitalized due to acute ischemic stroke (AIS). We also investigated the
incidence of clinical events, including major bleeding, stroke recurrence, in-hospital mortality,
readmission, and emergency room (ER) visits during the 3-year follow-up.
Methods
Study design and study population
We designed this retrospective multicenter observational study that was sponsored by BMS/
Pfizer Pharmaceuticals Korea Ltd. to explore the real-world practice of antithrombotic use in
Antithrombotics in AIS with NVAF before NOAC
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NVAF patients who were hospitalized due to AIS in Korea. This study conducted in nine univer-
sity hospitals, scattered nationwide, from July 2014 to March 2016. Through review of the existing
stroke registry databases of each center, patients who met the following criteria were identified
and enrolled: 1) Patients who were hospitalized due to AIS and discharged on or before December
31, 2008; 2) who had alleged diagnosis or electrocardiographic evidence of AF; 3) who had evi-
dence of relevant ischemic stroke on brain imaging; and 4) who were not enrolled in other inter-
ventional clinical studies during the study period (the first three years after discharge). Patients
who had prosthetic heart valve or were diagnosed as valvular AF were excluded.
Based on the maximally available resources to conduct this study and the expected precision
of ± 2.1% as 95% confidence intervals (CI) with a presumed prevalence of AF in Korean
patients with AIS (18.6%) [20], a sample size of 1,350 (150 patients at each participating center)
was calculated. Enrollment of study subjects was started from the patient who was hospitalized
for AIS in December, 2008 and proceeded retrogradely to reach 150 patients at each center.
Data collection, follow-up and outcome measures
Clinical data were collected through review of medical records by investigators or trained site
staffs at each center. To avoid information bias due to differences in data quality and quality of
the existing registry databases among centers, the registry data were used only for screening of
the study eligibility.
Time points for data collection were: at discharge, and 1 month (± 2 weeks), 2 months (± 2
weeks), 3 months (± 1 month), 6 months (± 1 month), 9 months (± 1 month), 12 months (± 1
month), 18 months (± 3 months), 24 months (± 3 months), 30 months (± 3 months), and 36
months (± 3 months) after discharge unless patients were lost to follow-up.
Information on the patients’ demographics features (age, sex, body mass index, and date of
admission) and clinical characteristics (stroke risk factors, CHADS2 scores, CHA2DS2–VASc
scores, and National Institute of Health Stroke Scale [NIHSS] at admission) at the time point
of discharge was collected. Information on antithrombotic use (VKA and antiplatelet agents)
and clinical events (major bleeding, stroke recurrence, death, readmission, and ER visits) was
captured repeatedly at the time points of 1, 2, 3, 6, 9, 12, 18, 24, 30, and 36 months after dis-
charge. The primary outcome measure was defined as a composite of stroke recurrence, major
bleeding, and death.
Modified individual time in therapeutic range
For each patient who received VKA only or VKA plus antiplatelet, INR values were collected
at every time point by chart review to assess the quality of anticoagulation. We estimated a
point prevalence of optimal INR level control (INR 2.0–3.0) at each time point. A modified
iTTR (individual time in therapeutic range)[21,22] was calculated as follows: First, after
excluding patients who had less than three times of INR measurements, those who had at least
90 evaluable days within the study period were included for iTTR calculation. The calculation
was made by, first, applying the Rosendaal’s linear interpolation method between two consecu-
tive INR measurements;15 Second, estimating a patient-specific proportion of INR measure-
ments fall within the value of 2.0 to 3.0 of INR among all of daily-based projected INR
measurements between two consecutive measurements dates (including the dates themselves)
over the study period; and the lastly, averaging these proportions over study subjects.
Statistical analysis
For summary statistics, mean (standard deviations, SD) and median (interquartile range IQR)
or number of subjects (percentage) were provided for numerical and categorical variables,
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respectively. For clinical events, the number of events and cumulative 3-month, 6-month,
1-year, 2-year, and 3-year event rates were calculated using the Kaplan–Meier product-limit
method.
We assessed the patterns of antithrombotic treatments within three years after discharge
(including at the time of discharge). After collecting information on the use of antithrombotic
medications, the point prevalence of medication was calculated at each time point. Treatment
pattern changes were then categorized as follows: First, the details of antithrombotic medica-
tion use in each patient at each time point were examined. Second, we assumed that a patient
took the same medication as he/she had taken on his/her last previous visit if there was no
record about the medication between recorded visits. If there was no information until the end
of follow-up after the last recorded visit, he or she was censored at that visit. Third, the
patients’ treatment profiles were categorized based on patterns of medication changes with
neglecting distinctions of time point (i.e., visit) and medication-discontinuation gaps between
visits. as a result, a total of 26 categories of medication patterns have been identified.
To investigate the effect of INR control on outcomes, VKA users were dichotomized by the
median of their modified iTTR’s, and their median survival time was compared using the log-
rank test.
All statistical analyses were performed with the SAS software version 9.4 (SAS Institute,
Gary, NC USA), and statistical significance was declared when a two-tailed p-value was less
than 0.05.
Ethical approval and patient consent
This study was approved by the institutional review boards of all the participating centers
(Seoul National University Bundang Hospital, Severance Hospital, Seoul National University
Hospital, SMG-SNU Boramae Medical Center, Inje University Ilsan Paik Hospital, Korea Uni-
versity Guro Hospital, Seoul St. Mary’s Hospital, Dong-A University Hospital and Samsung
Medical Center). All procedures have therefore been performed in accordance with the ethics
standards of the participating centers and with the 1964 Declaration of Helsinki and its later
amendments or comparable ethics standards. Informed consent was waived because of the ret-
rospective nature of the study.
Results
Patient characteristics and antithrombotic use
Of the 1,350 patients analyzed in this study, 54% were men and a mean age was 71 years
(Table 1). A median NIHSS score at admission was 7, a median CHADS2 score was 3.0, and a
median CHA2DS2-VASc score was 5.0. Median follow-up after discharge was 2.33 years (IQR,
0.18–2.97 years) and total follow-up duration is 2,214 person-years. Two-hundred forty-six
patients (18.2%) were lost to follow-up after discharge. Comparisons between patients with
and without VKA showed that those without VKA were more likely to be old, female, have
higher CHADS2 and CHA2DS2-VASc Scores.
At discharge, 95% of patients were on antithrombotic medications; 64% were on VKA only,
18% on antiplatelet drug only, and 12% on both (Table 2). Over time, the proportions of
patients being prescribed VKA alone or in combination with antiplatelet agents decreased
(77%, 55%, 50%, 45%, and 40% at discharge, 3 months, 1 year, 2 years, and 3 years, respec-
tively). However, when patients with missing information on antithrombotic use were
excluded from the denominators, the proportions remained fairly constant (77%, 82%, 85%,
82%, and 81% at discharge, 3 months, 1 year, 2 years, and 3 years, respectively; Fig 1). The pro-
portions of patients being prescribed antiplatelet drugs alone or in combination with VKA
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were also unchanged (30%, 28%, 28%, 31%, and 30% at discharge, 3 months, 1 year, 2 years,
and 3 years respectively).
Among antiplatelet drugs, aspirin was most common; about half of patients had aspirin
alone or with various combinations (Table 3). Among aspirin users, aspirin monotherapy was
a most common type whether they took VKA or not. As expected, antiplatelet polytherapy was
more common in the antiplatelet-only group than the VKA plus antiplatelet group. It should
be noted that the proportions of patients on antiplatelet monotherapy other than aspirin or
clopidogrel was not negligible in both of VKA plus antiplatelet and antiplatelet only groups.
Changes in antithrombotic medications and treatment patterns
We observed the highest rate of change in antithrombotic medications (15%) at 1 month after
discharge (Fig 2). Thereafter, change rates were stabilized (5–8% of patients). During the first 3
and last 6 months of follow-up, the most common change was a discontinuation of antithrom-
botic medications (1.3–3.4% of patients). In the intermediate period, the most common
change was from VKA to antiplatelet drugs (1.1–1.9% of patients).
We then analyzed treatment patterns within the 3-year follow-up period. The 531 patterns
that were initially identified were reduced to 387 after imputing no record of medication prior
Table 1. Baseline characteristics of the study population (n = 1,350).
Variables Total
(n = 1,350)
VKA�
(n = 1,126)
Non-VKA�
(n = 224)
P-value
Male† 729 (54.0) 633 (56.2) 96 (42.9) 0.0002
Age (years)‡ 70.8 (64.0–78.0) 70 (64.0–77.0) 77 (70.0–83.5) < .0001
BMI (kg/m2)‡ 23.3 (21.0–25.4) 23.5 (21.1–25.5) 22.6 (20.1–24.5) 0.0018
NIHSS at Admission‡ 7.0 (2.0–15.0) 6 (2.0–14.0) 12 (4–17) < .0001
Congestive heart failure† 148 (11.0) 122 (10.8) 26 (11.6) 0.7354
Hypertension† 923 (68.4) 770 (68.4) 153 (68.3) 0.9812
Diabetes mellitus† 345 (25.6) 287 (25.5) 58 (25.9) 0.8992
CHADS2 Score† 0.0031
2 223 (16.5) 203 (18.0) 20 (8.9)
3 489 (36.2) 412 (36.6) 77 (34.4)
4 475 (35.2) 385 (34.2) 90 (40.2)
5 150 (11.1) 116 (10.3) 34 (15.2)
6 13 (1.0) 10 (0.9) 3 (1.3)
CHA2DS2-VASc Score† < .0001
2 63 (4.7) 56 (5.0) 7 (3.1)
3 201 (14.9) 181 (16.1) 20 (8.9)
4 310 (23.0) 280 (24.9) 30 (13.4)
5 363 (26.9) 297 (26.4) 66 (29.5)
6 293 (21.7) 222 (19.7) 71 (31.7)
7 106 (7.9) 78 (6.9) 28 (12.5)
8 12 (0.9) 10 (0.9) 2 (0.9)
9 2 (0.1) 2 (0.2)
BMI, body mass index; NIHSS, national institutes of health stroke scale; IQR, interquartile range
P-value for comparing VKA with non-VKA subjects by Student’s t-test or chi-square test, as appropriate
�VKA is patients who have used VKA at least once. Non-VKA is patients who have never used VKA.
† Values are number of subjects (percentage)
‡ Values are median (IQR)
https://doi.org/10.1371/journal.pone.0202803.t001
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Table 2. Proportion of antithrombotic use at each time point during the 3-year follow-up (before/after excluding missing data from the denominator).
Discharge 1M 2M 3M 6M 9M 12M 18M 24M 30M 36M
VKA & antiplatelet (%) 12.4 / 12.4 10.8 /
13.5
9.2 / 12.9 8.7 / 13.2 8.3 / 13.4 8.2 / 14.2 8.6 / 14.6 8.8 / 14.8 8.0 / 14.5 7.4 / 14.0 7.0 / 14.1
VKA only (%) 64.2 / 64.2 55.0 /
68.6
50.0 /
70.4
45.9 /
69.1
42.7 /
69.4
40.2 /
69.5
40.9 /
69.9
40.1 /
67.5
37.3 /
67.3
35.4 /
66.8
33.1 /
67.1
Antiplatelet only (%) 18.0 / 18.0 11.2 /
14.0
10.2 /
14.3
9.7 / 14.5 8.7 / 14.2 8.2 / 14.2 8.1 / 13.8 9.1 / 15.4 8.6 / 16.8 8.7 / 16.5 8.0 / 16.3
None (%) 5.3 / 5.3 3.2 / 4.0 1.7 / 2.4 2.5 / 3.2 1.9 / 3.0 1.3 / 2.2 0.9 / 1.6 1.4 / 2.3 0.7 / 1.4 1.5 / 2.7 1.2 / 2.5
Missing� (%) 0 19.9 29.0 33.6 38.4 42.2 41.5 40.7 44.5 47.1 50.6
CHADS2�3/Missing (%)‡ 87.7 86.8 85.4 85.3 84.3 83.6 84.9 84.7 84.7 85.1
Death (N) 41 4 12 11 8 23 7 5 7 6
Observed patients at each time point†
(N)
1,350 1,350 1,309 1,305 1,293 1,282 1,274 1,251 1,244 1,239 1,232
Values are percentages if not indicated.
M indicate month(s).; VKA, vitamin K antagonists.
� Missing was defined as no information during ± 1 month at 1M, 2M, 3M, 6M, 9M and 12M and during ± 3 month at 18M, 24M, 30M and 36M.
† Number of observed patients at each time point (Calculated by number of total patients minus cumulated number of death at each time point)
‡ Proportions of patients whose CHADS2 scores were 3 or more at discharge among those whose medical records were missing at individual time points
https://doi.org/10.1371/journal.pone.0202803.t002
Fig 1. Antithrombotic use at each time point during the 3-year follow-up (Patients with no information were excluded from the denominators.). M indicate
month(s); VKA vitamin K antagonists.
https://doi.org/10.1371/journal.pone.0202803.g001
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to the patient’s last visit of 36 months with his/her last observed medication information. Fur-
ther disregard of time point distinction and medication-discontinuation gap between visits
resulted in a total of 26 treatment pattern categories (Fig 3). The rules defining these 26 catego-
ries are provided in Table 4. Maintaining VKA-only therapy during follow-up was the most
common treatment pattern (47.5%), followed by maintaining antiplatelet-only (12.4%), VKA
only (5.1%), and maintaining VKA therapy in combination with antiplatelet agents (5.0%).
Incidence of the primary outcome
The primary outcome event (a composite of stroke recurrence, major bleeding, and death)
occurred in 254 of the 1,350 patients during the follow-up period. The cumulative event rate at
Table 3. Types of antiplatelet agents prescribed to patients who were treated with antiplatelet only or VKA plus antiplatelet.
VKA + antiplatelet Antiplatelet only
Discharge 3M 12M 36M Discharge 3M 12M 36M
Aspirin + Clopidogrel + Other (%) - - - 1.2 0.4 - - 1.0
Aspirin + Clopidogrel (%) 8.3 7.0 5.5 3.5 29.2 28.6 25.2 19.1
Aspirin + Other (%) 2.4 0.9 0.9 - 2.1 1.6 1.0 6.1
Clopidogrel + Other (%) 0.6 1.6 1.8 - 1.7 3.2 2.9 2.0
Aspirin (%) 41.7 40.4 37.6 43.0 40.7 31.0 35.0 35.4
Clopidogrel (%) 9.5 8.8 13.8 14.0 12.8 19.8 14.3 29.3
Other antiplatelet monotherapy (%) 37.5 41.2 40.4 38.4 13.2 15.9 11.7 7.1
Observed patients at each time point� (N) 168 114 109 86 243 126 103 99
M indicate month(s); VKA vitamin K antagonists.
� Number of observed patients at each time point (Calculated by number of total patients minus cumulated number of death at each time point)
https://doi.org/10.1371/journal.pone.0202803.t003
Fig 2. Change of antithrombotic medication at each time point. M indicate month(s); VKA vitamin K antagonists.
https://doi.org/10.1371/journal.pone.0202803.g002
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3 years was 27.0% (95% CI, 24.0–30.0%; Fig 4). One-hundred six strokes, 48 major bleedings,
and 124 deaths occurred. Among 106 strokes, 67 were ischemic, 25 hemorrhagic and 18 unde-
termined. The 3-year cumulative event rates of stroke recurrence, major bleeding, and death
were 13.1% (95% CI, 10.7–15.6%), 5.5% (95% CI, 4.0–7.1%), and 13.7% (95% CI, 11.3–16.0%),
respectively. Readmission occurred in 120 patients with a 3-year cumulative event rate of
13.6% (95% CI, 11.3–16.0%). A total of 80 patients visited the ER within the follow-up period,
with a 3-year cumulative rate of 9.6% (95% CI, 7.6–11.7%). Annualized incidence rates of pri-
mary outcome events, each component of primary outcome measure, re-admission, and ER
visit are presented in Table 5.
The 3-year cumulative event rates of the primary outcome differed according to the treat-
ment patterns. It was highest in patients who started with VKA therapy in combination with
antiplatelet drugs but who discontinued therapy during follow-up and did not take any antith-
rombotic medications until the end of follow-up (100%; Fig 3). This was followed by those
who started with VKA therapy in combination with antiplatelet drugs, changed to antiplatelet-
only, and discontinued it after then (78%). Among the 10 most frequent types, the highest rate
Fig 3. Number of patients according to treatment patterns and proportions who experienced primary outcome events according to the types (The definitions of
treatment patterns are provided in Table 4.). M indicate month(s); VKA vitamin K antagonists. �Note. If there is one symbol in the pattern category, this means that
only one treatment is maintained. If there are two or more symbols in the pattern category, this category indicates that the treatment was changed.
https://doi.org/10.1371/journal.pone.0202803.g003
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Table 4. Rules for defining treatment patterns.
1. Rules for dealing with missing data on the pharmaceutical prescriptions (531 patterns before rule application/ 387 patterns after rule application)
1) Applicable to all prescriptions
1-1) In a case where a medication prescription record was unavailable for a specific follow-up time, and the prescription records for the preceding and following follow-
up time were available, the prescription at the specific follow-up time was presumed as the same as that received at the preceding follow-up time.
1-2) If there were no the prescription records after the last prescription, the missing data was not redefined.
(Ex.) In a case where at 9 and 18 months after discharge, prescriptions for medication were available, and at 12 months after discharge, medication prescription was
unavailable, the prescribed medication at 12 months after discharge was defined as the same as that prescribed at 9 months after discharge.
(Ex 1) Pattern ID 87
① Before application
Pattern ID No. of patients Discharge 1M 2M 3M 6M 9M 12M 18M 24M 30M 36M
87 2 ◎ ◎ ◎ ◎ ◎ ◎
② After application
Pattern ID No. of patients Discharge 1M 2M 3M 6M 9M 12M 18M 24M 30M 36M
87 2 ◎ ◎ ◎ ◎ ◎ ◎ ◎
M indicates month(s).
2) Applicable to ’VKA & Antiplatelet’ or ’VKA only’ groups
2–1) If a prescription at discharge was ’VKA & Antiplatelet’ or ’VKA only’ and there were no prescription records for the next two follow-up times with a prescription
available at 3 months after discharge, the missed records at 1 month and 2 months, which were within 3 months after discharge, were regarded as the same as the
prescription record at discharge.
(Ex 2) Pattern ID 29
① Before application
Pattern ID No. of patients Discharge 1M 2M 3M 6M 9M 12M 18M 24M 30M 36M
29 5 ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎
② After application
Pattern ID No. of patients Discharge 1M 2M 3M 6M 9M 12M 18M 24M 30M 36M
29 5 ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎
M indicates month(s).
3) Applicable to ’Antiplatelet only’ groups
In a case where a prescription at 2 months after discharge was ‘antiplatelet only’ and there were no prescription records at 3 months and 6 months after discharge, and
the prescription record at 9 months after discharge was available, the missed data at 3 and 6 months were defined as ‘antiplatelet only’.
(Ex 3) Pattern ID 29
① Before application
Pattern ID No. of patients Discharge 1M 2M 3M 6M 9M 12M 18M 24M 30M 36M
29 5 ◎ � ● �
② After application
Pattern ID No. of patients Discharge 1M 2M 3M 6M 9M 12M 18M 24M 30M 36M
29 5 ◎ ◎ � � � ● ● �
M indicates month(s).
2. Additional rules for treatment pattern simplification (203 patterns after rule application)
1) If no prescription records were at the midpoint of the follow-up, the missed data were completed with prescription records at the preceding follow-up time.
2) If there were no prescription records before completion of the follow-up period after the last prescription record, missing data up to 36 months were completed by using
the last prescription record.
(Ex) Pattern ID 270
① Before application
Pattern ID No. of patients Discharge 1M 2M 3M 6M 9M 12M 18M 24M 30M 36M
270 1 ● ● ● ◎ ◎ ◎
② After applicating the rule of No. 2–1)
Pattern ID No. of patients Discharge 1M 2M 3M 6M 9M 12M 18M 24M 30M 36M
270 1 ● ● ● ◎ ◎ ◎ ◎ ◎
② After applicating the rule of No. 2–2)
Pattern ID No. of patients Discharge 1M 2M 3M 6M 9M 12M 18M 24M 30M 36M
270 1 ● ● ● ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎
M indicates month(s).
Rules 1 and 2 were applied to correct all the prescription patterns without missing data from discharge time to 36 months after discharge. Finally, a total of 26 treatment
patterns were generated.
https://doi.org/10.1371/journal.pone.0202803.t004
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was observed in patients who starting with VKA-only therapy and discontinued it without
restart mid-follow-up (70.2%). The second highest rate was seen in patients who started with
antiplatelet-only therapy and discontinued it without restart (66.7%). Among treatment types
with no change in antithrombotic medication, the 3-year cumulative event rates of the primary
outcome ranged between 6.6% and 16.8%; these rates were lower than the rates observed for
treatment types with changes in antithrombotic medications.
Fig 4. Cumulative incidence curve for clinical events.
https://doi.org/10.1371/journal.pone.0202803.g004
Table 5. Incidence rates of outcome events.
Number of events Incidence rate per
100 person-years
95% CI
Primary events 254 11.47% 10.06–13.96%
Major bleeding 48 2.17% 1.55–5.08%
Stroke recur 106 4.79% 3.88–7.62%
Death 124 5.60% 4.61–8.40%
Re-admission 120 5.42% 4.45–8.22%
ER visit 80 3.61% 4.45–8.22%
https://doi.org/10.1371/journal.pone.0202803.t005
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International normalized ratios and primary outcomes by modified iTTR
A total of 1,253 patients had one or more INR measurement(s) during follow-up (mean num-
ber of INR measurements: 5.61). The point prevalence of optimal INR (2–3) in patients taking
VKA alone or in combination with antiplatelet drugs (n = 1,028) was highest at discharge (586
of 1028, 57.0%), lowest at 2 months after discharge (209 of 564, 37.1%) and then increased
slowly until the end of follow-up (Fig 5). A median modified iTTR was 46.9% (IQR, 27.3–
64.3%) and a mean modified iTTR was 45.6% (SD, 25.7%). The proportion of patients who
achieved modified iTTR >60% was 31.4%.
VKA users were then categorized into a well-controlled INR group and a poorly-controlled
INR group (modified iTTR�47.0% vs.<47.0%). The 3-year cumulative primary outcome
rates were 15.7% and 24.5% in the well- and poorly-controlled groups, respectively; the differ-
ence was statistically significant (p = 0.015; Fig 6).
Fig 5. Point prevalence of optimal INR levels in the VKA only and the VKA plus antiplatelet groups at each time point. M indicate month(s).
https://doi.org/10.1371/journal.pone.0202803.g005
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Discussion
Of the 1,350 patients who were hospitalized due to AIS and had AF in our study, 77% were dis-
charged with VKA and this proportion decreased over time (40% at 3 years). We could find
diverse patterns of antithrombotic use during 3 years after stroke. Primary outcome rates dif-
fered by these patterns, and discontinuation of antithrombotic agents, especially VKA, seemed
to be associated with primary outcome. Among the VKA users, the poorly-controlled INR was
at higher risk for primary outcome than the well-controlled INR group.
A multicenter registry-based study that examined the patterns of antithrombotic use in AIS
patients with AF in the United States showed that 87% were on OAC therapy at discharge.(8)
Another multicenter registry-based study in Canada reported an OAC prescription rate of
70% at discharge.[11] It should be noted that the enrollment periods of the study subjects in
these three studies (including ours) were 2008 or earlier. A recent multicenter-registry study in
Japan, which enrolled study subjects between 2011 and 2014, reported a much higher OAC
prescription rate at discharge (96%); VKA was prescribed in 56% and NOACs in 40%.[23] The
use of NOACs in the treatment of AF was officially allowed between 2011 and 2013 in Korea
(dabigatran in March 2011, rivaroxaban in April 2012, and apixaban in February 2013), but it
was limitedly allowed to patients who experienced bleedings or ischemic events during taking
VKA or had contra-indications for VKA. In 2015, indications for NOACs were expanded like
other developed countries and an increase in the use of NOAC is expected.
The OAC prescription rate decreased over time in our study (77% at discharge, 50% at 1
year, 45% at 2 years, and 40% at 3 years). Data from the Adherence eValuation After Ischemic
Stroke Longitudinal (AVAIL) registry in the United States showed an OAC prescription rate
of 87% at discharge and 78% at 1 year after discharge.[8] In the Riks-Stroke registry of Sweden,
rates were 89%, 65%, and 45% at 4 months, 1 year, and 2 years, respectively.[12] The propor-
tions of patients who were excluded from analysis due to lack of follow-up data at the last
Fig 6. Primary outcome events according to modified iTTR. iTTR, individual time in therapeutic range.
https://doi.org/10.1371/journal.pone.0202803.g006
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follow-up were 6.0% in the AVAIL registry and about 1% in the Riks-Stroke Registry; in con-
trast, it was 50% in our study. This higher proportion of missing information in our study may
be attributed to collection of data by retrospective chart review and years of time gaps between
patient visits at out-patient clinic and data collection. When we excluded patients with missing
follow-up data from the denominators, OAC prescription rates were relatively constant during
the 3-year follow-up period, ranging between 81% and 83%. True OAC prescription rates
seem to exist between them; a study linking data from the registry and national insurance
claim databases might provide answers.
Antiplatelet drugs alone or in combination with VKAs were given to 30% of patients at dis-
charge. This rate was relatively constant during the 3-year follow-up period; it is significantly
lower than the rates reported in Western countries: 47% and 46% at discharge and at 1 year,
respectively, for the AVAIL Registry[8] and 53% at discharge for the Ontario Stroke Registry
of Canada.[11] This difference could be explained by differences in the proportions of patients
who were being prescribed VKAs in combination with antiplatelet agents. The rate ranged
between 12% and 14% in our study, whereas it was 31% in the Ontario Stroke Registry and
36% in the AVAIL Registry. The lower rates in our study can be explained, at least partly, by
the lower prevalence of coronary heart disease (CHD) in Korean ischemic stroke patients with
AF. We could not gather information on CHD in this study; however, according to a recent
report from Korea, the CHD prevalence in AIS patients with AF was 16%;[24] in contrast, it
was 37% in the AVAIL Registry.
As expected, aspirin was a most commonly prescribed antiplatelet drug in patients taking
VKA in combination with antiplatelet agents in our study (52% and 44% at discharge and 1
year, respectively) as well as in those on antiplatelet-only therapy (72% and 61% at discharge
and 1 year, respectively). In the AVAIL registry, aspirin was prescribed to 95% and 98% of
patients taking VKA in combination with antiplatelet agents at discharge and 1 year, respec-
tively; and to 85% and 89% of patients taking antiplatelet drugs only at discharge and 1 year,
respectively.[8] The use of antiplatelet drugs other than aspirin seems to be higher in our study
when compared to the AVAIL registry.
To the best of our knowledge, this study might be the first one to report changes in antith-
rombotic medication patterns during a long-term follow-up period in AIS patients with AF.
Treatment patterns were more complex than expected (Fig 3). During the first 3 years after
stroke, 69% of patients did not change antithrombotic medications significantly. The remain-
ing 31%, however, changed treatment heavily; most common patterns were stopping OAC
without restart (17%). Fig 3 may suggest an association between discontinuation of antithrom-
botic medications without restart and occurrence of clinical events, but it should be inter-
preted cautiously and confirmed by a well-designed prospective study in the future.
We found a mean modified iTTR of 45.6% in this study; the proportion of patients who
achieved a modified iTTR >60% was 31.4%. In pivotal NOAC trials, the mean TTR of Korean
patients randomized to warfarin was much lower than the average TTR of overall study popu-
lations.[16, 17, 25, 26] This study confirms that TTR in practice might be much lower than
that in clinical trial settings in Korea. A Korean single center study reported a TTR of 57.5% in
AF-related stroke patients whose warfarin therapy was managed by a formal anticoagulation
clinic.[27] As expected, patients with higher modified iTTRs had lower rates of primary out-
come events than those with lower modified iTTRs.
This study has several limitations. First, most of the participating centers are large tertiary
hospitals; therefore, the study subjects might be not representative of the Korean stroke popu-
lation with AF. Second, underestimations of outcome events and biases due to inadequate
information might have been inevitable as most data on antithrombotic medications, INRs,
and outcome events were based on retrospective review of medical records. Third, consensus
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about the classification of long-term antithrombotic treatment patterns was lacking. The arbi-
trariness of our classification might affect the generalization of our results. Fourth, although
lost to follow-up and missing information were unavoidable in this retrospective study, the
attrition rate of 50% in our study was higher than expected. Thus, caution should be exerted
when trying to generalize our results. Fifth, we could not collect information on reasons why
antithrombotic medications were stopped or changed. Therefore, we could not exclude that
backgrounds of changing treatment differed even within the same treatment patterns: for
example, one stopped VKA due to serious bleeding but another did due to poor compliance.
Despite these limitations, our study, to the best of our knowledge, was the first to explore
antithrombotic treatment patterns throughout a long-term follow-up period after AIS in
Korean patients with AF. Our study revealed that before the introduction of NOACs in Korea
in 2015, <80% of AIS patients with AF were discharged with OAC therapy; thereafter, the
OAC prescription rate seemed to gradually decrease. When compared to other Western coun-
tries, antiplatelet drugs were used less frequently in our study population; this can be mostly
explained by the less frequent use of antiplatelet agents in combination with VKA. The lower
prevalence of CHD in the Korean population might be an explanation. Third, aspirin was the
most common antiplatelet drug; however, the use of antiplatelet medications other than aspi-
rin was more frequent than expected. Fourth, we observed complex patterns of antithrombotic
treatment during the 3-year follow-up period. Antithrombotic medications were often discon-
tinued without being restarted; this might have been associated with clinical events. Fifth, INR
control status in VKA users was poorer in practice than expected (achieved modified iTTR
>60% of 31.4%). A future prospective study should elucidate the clinical meanings and conse-
quences of these complex treatment patterns.
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